Clinical Trial Update: Hydroxychloroquine Treatment for Severe COVID-19 Pulmonary Infection (HYDRA Trial) [Phase 3]

View source ↗

Summary

Phase 3 trial completed evaluating hydroxychloroquine for severe COVID-19 pneumonia.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Syndrome

Drugs mentioned

• Hydroxychloroquine (hydroxychloroquine)

Snippet

Sponsor: National Institute of Respiratory Diseases, Mexico | Conditions: COVID-19, Severe Acute Respiratory Syndrome | Phase 3 | Status: COMPLETED